
Lipidio Pharma: Advancing molecules for dermatological and metabolic diseases treatment.
Lipidio Pharmaceuticals, founded to address significant unmet medical needs, is dedicated to developing innovative treatments for dermatological and metabolic diseases. Their core mission is to advance molecules that can effectively treat conditions such as acne, sebaceous hyperplasia, nonalcoholic steatohepatitis (NASH), and obesity. By focusing on these prevalent health issues, Lipidio aims to improve patient outcomes and quality of life through cutting-edge pharmaceutical solutions.
Notable achievements for Lipidio Pharmaceuticals include presenting at prestigious conferences such as the BIOCOM Global Life Sciences Partnering Conference and the Dermatology Summit. The company has successfully closed a Series A extension financing round, raising over $20 million to further their research and development efforts. This financial backing and industry recognition underscore Lipidio's potential impact on the healthcare sector, particularly in addressing chronic dermatological and metabolic conditions.

OrsoBio
orsobio.com

LipimetiX

Resolvyx Pharmaceuticals

Lipocine
lipocine.com

Adipo Therapeutics

Timber Pharmaceuticals

Arcutis Biotherapeutics
arcutis.com

Eolo Pharma
eolo-pharma.com

Lobesity Investors

Lipella Pharmaceuticals
lipella.com

Astria Therapeutics
astriatx.com

DermBiont
dermbiont.com

KinDex Pharmaceuticals

Aria Pharmaceuticals

BodyBio
bodybio.co.uk
Companies similar to Lipidio Pharmaceuticals include OrsoBio, LipimetiX, Resolvyx Pharmaceuticals and Lipocine.
Lipidio Pharmaceuticals was founded in 2018.
Lipidio Pharmaceuticals' headquarters is located in San Diego, CA, US.
Lipidio Pharmaceuticals' most recent funding round was for $20M (USD) in November 2022.
As of Nov 10, 2022, Lipidio Pharmaceuticals has raised a total of $20M (USD).
Lipidio Pharmaceuticals has 5 employees as of Feb 5, 2024.